Stocktoria
Universe Pharmaceuticals INC UPC
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-03-23
Universe Pharmaceuticals INC financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $17.9B | $23.0B | $32.3B | $40.1M | $48.0M | $30.7M |
| Gross profit | $6.3B | $6.1B | $10.3B | $21.9M | $25.3M | $14.1M |
| R&D expense | $671.8M | $3.0B | $4.9B | $7.6M | $5.5M | $583,125 |
| Operating income | -$2.9B | -$8.0B | -$4.0B | -$7.0M | $13.6M | $10.3M |
| Interest expense | $289.4M | $304.5M | $190.2M | $162,400 | $101,604 | $123,760 |
| Income tax | — | $606.7M | $2.3B | $815,322 | $2.4M | $2.5M |
| Net income | -$3.7B | -$8.7B | -$6.6B | -$7.9M | $11.3M | $7.6M |
| EPS (diluted) | $-8.06 | $-626.96 | $-1089.21 | $-1309.11 | $3.58 | $0.47 |
| Operating cash flow | -$5.1B | -$9.5B | $1.1B | -$1.3M | -$2.1M | $6.1M |
| Free cash flow | -$5.3B | -$9.7B | $1.1B | -$1.4M | -$2.5M | $6.1M |
| Cash & equivalents | — | — | — | — | $8.1M | $10.1M |
| Inventory | $2.2B | $1.7B | $3.3M | $2.2M | $2.5M | $1.9M |
| Total assets | $69.3B | $68.0B | $41.7M | $59.5M | $70.1M | $28.8M |
| Total liabilities | $13.2B | $22.5B | $13.8M | — | — | — |
| Shareholders' equity | $56.1B | $45.5B | $28.0B | $35.3B | $47.0M | $20.8M |
Growth · year-over-year · Revenue CAGR 257.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -22.4% | -28.7% | +80383.8% | -16.3% | +56.3% | — |
| Net income growth | — | — | — | -169.9% | +49.8% | — |
| EPS growth | — | — | — | -36667.3% | +661.7% | — |
| Free cash flow growth | — | -1005.7% | — | — | -141.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.